STOCK TITAN
  1. Home
  2. Sec-filings
  3. BSX
  4. [Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Boston Scientific (NYSE: BSX) CEO discloses RSU vesting, tax shares and new grants

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Boston Scientific Chairman, President & CEO Michael F. Mahoney reported several equity compensation transactions dated February 12, 2026. He acquired 13,704 shares of common stock through the exercise of restricted stock units at $0.0000 per share, then disposed of 6,626 shares at $74.12 per share to cover tax obligations, leaving 1,418,813 common shares held directly.

Mahoney also received a new grant of 55,652 restricted stock units and a stock option for 131,329 shares with an exercise price of $74.12 per share, both vesting in four equal annual installments beginning February 12, 2027. In addition, 213,679 common shares are held indirectly in a trust.

Positive

  • None.

Negative

  • None.
Insider Mahoney Michael F
Role Chairman, President & CEO
Type Security Shares Price Value
Exercise Restricted Stock Units 13,704 $0.00 --
Grant/Award Restricted Stock Units 55,652 $0.00 --
Grant/Award Stock Option (Right to Buy) 131,329 $0.00 --
Exercise Common Stock 13,704 $0.00 --
Tax Withholding Common Stock 6,626 $74.12 $491K
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 27,408 shares (Direct); Stock Option (Right to Buy) — 131,329 shares (Direct); Common Stock — 1,425,439 shares (Direct); Common Stock — 213,679 shares (Indirect, By Trust)
Footnotes (1)
  1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mahoney Michael F
(Last) (First) (Middle)
300 BOSTON SCIENTIFIC WAY
(Street)
MARLBOROUGH MA 01752-1234
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman, President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/12/2026 M 13,704 A $0.0000(1) 1,425,439 D
Common Stock 02/12/2026 F 6,626 D $74.12 1,418,813 D
Common Stock 213,679 I By Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/12/2026 M 13,704 (2) 02/12/2028(2) Common Stock 13,704 $0.0000 27,408 D
Restricted Stock Units (1) 02/12/2026 A 55,652 (3) 02/12/2030(3) Common Stock 55,652 $0.0000 55,652 D
Stock Option (Right to Buy) $74.12 02/12/2026 A 131,329 (4) 02/12/2036 Common Stock 131,329 $0.0000 131,329 D
Explanation of Responses:
1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
4. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
/s/ Susan Thompson, Attorney-in-Fact 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BSX CEO Michael Mahoney report on February 12, 2026?

Michael Mahoney reported equity compensation activity on February 12, 2026, including RSU vesting, tax-share withholding, and new grants. These transactions reflect routine executive compensation rather than open-market buying or selling of Boston Scientific common stock.

How many Boston Scientific (BSX) shares does Michael Mahoney hold directly after this Form 4?

After the reported transactions, Michael Mahoney directly holds 1,418,813 shares of Boston Scientific common stock. This figure reflects the net result of RSU exercises and shares withheld for taxes as disclosed in the February 12, 2026 insider filing.

What new restricted stock units did BSX grant to Michael Mahoney?

Boston Scientific granted Michael Mahoney 55,652 new restricted stock units. Each unit represents a commitment to deliver one share of common stock, vesting in four equal annual installments starting February 12, 2027, according to the footnotes in the Form 4 filing.

What stock options did Michael Mahoney receive from Boston Scientific (BSX)?

Michael Mahoney received a stock option covering 131,329 shares of Boston Scientific common stock at an exercise price of $74.12 per share. The option vests in four equal annual installments beginning February 12, 2027, as described in the Form 4 footnotes.

Were any Boston Scientific (BSX) shares disposed of to pay taxes in this Form 4?

Yes. The filing shows 6,626 shares of Boston Scientific common stock disposed of at $74.12 per share. The transaction is coded “F,” indicating shares were withheld or delivered to satisfy tax obligations related to equity compensation, not an open-market sale.

Does Michael Mahoney have indirect ownership of Boston Scientific (BSX) shares?

Yes. In addition to his direct holdings, the Form 4 reports 213,679 Boston Scientific common shares held indirectly by a trust. This indirect position is labeled with ownership type “I” and nature of ownership described as “By Trust” in the filing.